The SURMOUNT-5 trial, published in the New England Journal of Medicine, compared tirzepatide directly against semaglutide in people with obesity
In a recent large cross-sectional study evaluating 9823 T2DM patients from around the world (including Brazil), 34.8% of patients had established cardiovascular disease (CVD), of whom 85.8% had atherosclerotic cardiovascular disease (ASCVD) [8]
Article PubMed Google Scholar Download references Related Articles Obesity drugs: huge study identifies new health risks Dozens of new obesity drugs are coming: these are the ones to watch Why do obesity drugs seem to treat so many other ailments
Our Lysine infusion delivers this vital building block directly to your body, helping support recovery, healthy collagen formation, and immune function so you can feel and perform your best
Glutathione bypasses the body's slow and frequently unsuccessful digestive process when taken intravenously